Evidence map›Paper›PMID 35987521›Full record

ArticleThe Medical journal of Australia2022

Long term risk of distant metastasis in women with non-metastatic breast cancer and survival after metastasis detection: a population-based linked health records study.

Sarah Sally J Lord, Benjamin Daniels, Belinda E Kiely, Dianne L O'Connell, Jane Beith, Sallie Pearson, Kim-Lin Chiew, Max K Bulsara, Nehmat Houssami

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Medical journal of Australia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Sarah Sally J LordThe University of Notre Dame, Sydney, NSW.ORCID 0000-0003-2763-5949
Benjamin DanielsCentre for Big Data Research in Health, University of New South Wales, Sydney, NSW.ORCID 0000-0001-8617-6055
Belinda E KielyNHMRC Clinical Trials Centre, the University of Sydney, Sydney, NSW.ORCID 0000-0002-1662-3523
Dianne L O'ConnellThe Daffodil Centre, the University of Sydney and Cancer Council NSW, Sydney, NSW.
Jane BeithCentral Clinical School, Chris O'Brien Lifehouse, Sydney, NSW.
Sallie PearsonCentre for Big Data Research in Health, University of New South Wales, Sydney, NSW.
Kim-Lin ChiewPrincess Alexandra Hospital, Brisbane, QLD.
Max K BulsaraInstitute of Health Research, University of Notre Dame, Fremantle, WA.
Nehmat HoussamiThe Daffodil Centre, the University of Sydney and Cancer Council NSW, Sydney, NSW.ORCID 0000-0002-3641-952X
The University of Sydney · AUUniversity of Notre Dame · USUNSW Sydney · AUChris O’Brien Lifehouse · AUPrincess Alexandra Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo estimate the long term risk of distant metastases (DM) for women with initial diagnoses of non-metastatic breast cancer; to estimate breast cancer-specific and overall survival for women with DM.

designPopulation-based health record linkage study. SETTING,

participantsWomen diagnosed with localised or regional primary breast cancer recorded in the NSW Cancer Registry, 2001-2002. MAJOR OUTCOME MEASURES: Time from breast cancer diagnosis to first DM, time from first DM to death from breast cancer. SECONDARY OUTCOME: time to death from any cause.

results6338 women were diagnosed with non-metastatic breast cancer (localised, 3885; regional, 2453; median age, 59 years [IQR, 49-69 years]). DM were recorded (to 30 September 2016) for 1432 women (23%; median age, 62 years [IQR, 51-73 years]). The 14-year cumulative DM incidence was 22.2% (95% CI, 21.1-23.2%; localised disease: 14.3% [95% CI, 13.2-15.4%]; regional disease: 34.7% [95% CI, 32.8-36.6%]). Annual hazard of DM was highest during the second year after breast cancer diagnosis (localised disease: 2.8%; 95% CI, 2.3-3.3%; regional disease: 9.1%; 95% CI, 7.8-10.3%); from year five it was about 1% for those with localised disease, from year seven about 2% for women with regional disease at diagnosis. Five years after diagnosis, the 5-year conditional probability of DM was 4.4% (95% CI, 3.7-5.1%) for women with localised and 10.4% (95% CI, 9.1-12.0%) for those with regional disease at diagnosis. Median breast cancer-specific survival from first DM record date was 28 months (95% CI, 25-31 months); the annual hazard of breast cancer death after the first DM record declined from 36% (95% CI, 33-40%) during the first year to 14% (95% CI, 11-18%) during the fourth year since detection.

conclusionsDM risk declines with time from diagnosis of non-metastatic breast cancer, and the annual risk of dying from breast cancer declines with time from initial DM detection. These findings can be used to inform patients at follow-up about changes in risk over time since diagnosis and for planning health services.

Indexed as

Breast NeoplasmsFemaleHumansIncidenceMiddle AgedNeoplasm MetastasisRegistriesBreast neoplasmsEpidemiology

Identifiers

PMID35987521
PMCPMC9804703
OpenAlexW4292806447

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.